Loading clinical trials...
Loading clinical trials...
Find 410 clinical trials for breast cancer near Minneapolis, Minnesota. Connect with research centers in your area.
Showing 281-300 of 410 trials
NCT02911155
Background: The field of nuclear medicine has changed a lot in the past decades. Technology has gotten better, so patients are exposed to less radiation. But now workers are doing procedures more often and using lead aprons less. So they may be exposed to more radiation. This may put them at higher risk for cancers and other health problems that are related to radiation. Researchers want to collect data from technologists to learn more about the risks and appropriate doses of radiation. Objective: To learn more about the risks and appropriate doses of radiation for nuclear medicine technologists. Eligibility: Adults who were first certified in nuclear medicine technology in the United States after 1980. They must be living in the United States. They must not be participants in the USRT study. Design: Participants will be recruited online. Participants will complete an online survey. It will take about a half hour. This will have questions about their work with nuclear medicine procedures. There will be questions about the kinds of procedures and how often they do them. Participants will give a short work history. This will include the names of current and past employers. Participants will allow researchers to get records of their film badge dose readings. These will come from dosimetry providers. Dosimetry data will not be shared with participants. Researchers can t ensure the how accurate or complete the data are.
NCT00684983
This phase II trial studies capecitabine and lapatinib ditosylate to see how well they work compared with capecitabine, lapatinib ditosylate, and cixutumumab in treating patients with previously treated HER2-positive stage IIIB-IV breast cancer. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with cixutumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether capecitabine and lapatinib ditosylate are more effective when given with or without cixutumumab in treating breast cancer that has spread nearby or to other areas of the body.